ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 538

Ankylosing Spondylitis Associated Endoplasmic Reticulum Aminopeptidase 1 Variants Alter The Unfolded Protein Response

Nigil Haroon1,2,3 and Zhenbo Zhang3, 1Rheumatology, University Health Network, Toronto, ON, Canada, 2Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada, 3Toronto Western Research Institute, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), cytokines and genetic disorders, Functional Genomics

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Endoplasmic reticulum aminopeptidase 1 (ERAP1) has recently been identified to be strongly associated with HLA-B27 positive AS. We have shown that ERAP1 variants cause changes in free heavy chain (FHC) expression on peripheral blood mononuclear cells from HLA-B27 positive patients as well as on B27-expressing C1R cells by in vitro assays. Unfolding of HLA-B27 and the formation of FHC can cause the release of inflammatory cytokines by triggering the unfolded protein response (UPR). We tested if ERAP1 variants can affect the UPR.

Methods:

Endogenous ERAP1 was silenced in C1R-HLA-B27 cells with ERAP1-shRNA (C1RERAP1sh). C1R cells with stable ERAP1-shRNA expression were identified by GFP expression and were selected with puromycin. Scrambled sequence shRNA was used as control. Western blot (WB) for ERAP1 suppression was done using ERAP1 antibody.

We then transfected either the common variant ERAP1 (ERAP1WT) or one of the two AS-associated ERAP1 variants, K528R or Q730E into the C1RERAP1sh cells. Lentivirus expression vector alone was used as control and exogenous ERAP1 expression was tracked with HA-tag. Stable cells expressing ERAP1WT or ERAP1-variants were selected by hygromycin. UPR was measured using PCR for spliced variants of XBP-1 and by qRT-PCR and western blot for BiP, CHOP and ATF-6. 

Results:

Almost all C1R cells that were selected by antibiotics were GFP positive indicating stable ERAP1-shRNA expresion. Using WB we noted more than 90% suppression of ERAP1 and more than 75% suppression by qRT-PCR in C1RERAP1sh, compared to the cells with scrambled-sequence shRNA. Anti-HA WB showed uniform strong expression of ERAP1WT and variant forms of ERAP1 in the respective cell lines.

Spliced XBP1, a marker of UPR, was upregulated in the C1RERAP1sh cells. Re-introduction of ERAP1 (C1R-ERAP1WT cells) reduces the UPR response while C1R-ERAP1K528R and C1R-ERAP1Q730E cells expressing the ERAP1 variants had higher UPR activation compared to C1R-ERAP1WT cells. Other UPR markers including BiP, CHOP and ATF6 expression followed the same pattern with AS-associated variants leading to higher UPR.

Conclusion:

ERAP1 suppression leads to increased UPR. AS-associated ERAP1-variants, which are known to have reduced function, leads to more UPR compared to the common variant of ERAP1.


Disclosure:

N. Haroon,
None;

Z. Zhang,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ankylosing-spondylitis-associated-endoplasmic-reticulum-aminopeptidase-1-variants-alter-the-unfolded-protein-response/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology